Compare TROX & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TROX | RARE |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2012 | 2013 |
| Metric | TROX | RARE |
|---|---|---|
| Price | $3.43 | $15.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $5.50 | ★ $26.25 |
| AVG Volume (30 Days) | 1.9M | ★ 3.7M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,898,000,000.00 | $673,000,000.00 |
| Revenue This Year | $13.24 | $12.87 |
| Revenue Next Year | $4.93 | $30.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $2.86 | $12.73 |
| 52 Week High | $10.59 | $39.89 |
| Indicator | TROX | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 32.68 | 49.65 |
| Support Level | N/A | $13.95 |
| Resistance Level | $4.53 | $23.44 |
| Average True Range (ATR) | 0.18 | 0.73 |
| MACD | 0.02 | 0.39 |
| Stochastic Oscillator | 30.66 | 81.17 |
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.